Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Utilization of primary health care services among Syrian refugee and Lebanese women targeted by the ICRC program in Lebanon: a cross-sectional study.

Truppa C, Leresche E, Fuller AF, Marnicio AS, Abisaab J, El Hayek N, Zmeter C, Toma WS, Harb H, Hamadeh RS, Leaning J.

Confl Health. 2019 Mar 15;13:7. doi: 10.1186/s13031-019-0190-4. eCollection 2019.

2.

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.

Sarosy GA, Hussain MM, Seiden MV, Fuller AF, Nikrui N, Goodman A, Minasian L, Reed E, Steinberg SM, Kohn EC.

Cancer. 2010 Mar 15;116(6):1476-84. doi: 10.1002/cncr.24861.

3.

Surgical management of the subdiaphragmatic mass: a sequential combined approach with laparoscopy followed by posterior thoracotomy.

Orezzoli JP, Wain JC, Fuller AF Jr.

Int J Gynecol Cancer. 2009 Feb;19(2):294-9. doi: 10.1111/IGC.0b013e31819c13f5.

PMID:
19396012
4.

Epithelioid angiosarcoma of the uterus: a review of management.

Olawaiye AB, Morgan JA, Goodman A, Fuller AF Jr, Penson RT.

Arch Gynecol Obstet. 2008 Nov;278(5):401-4. doi: 10.1007/s00404-008-0727-z. Epub 2008 Jul 19. Review.

PMID:
18642010
5.

Prognostic implication of endometriosis in clear cell carcinoma of the ovary.

Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF.

Gynecol Oncol. 2008 Sep;110(3):336-44. doi: 10.1016/j.ygyno.2008.05.025. Epub 2008 Jul 18.

PMID:
18639330
6.

Hope.

Penson RT, Gu F, Harris S, Thiel MM, Lawton N, Fuller AF Jr, Lynch TJ Jr.

Oncologist. 2007 Sep;12(9):1105-13. Review.

7.

Primary treatment of Bartholin's gland carcinoma with radiation and chemoradiation: a report on ten consecutive cases.

López-Varela E, Oliva E, McIntyre JF, Fuller AF Jr.

Int J Gynecol Cancer. 2007 May-Jun;17(3):661-7.

PMID:
17504379
8.

PET-CT vs. CT alone in ovarian cancer recurrence.

Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF, Fuller AF, Hahn PF.

Abdom Imaging. 2008 Jan-Feb;33(1):112-8.

PMID:
17404789
9.

Uterine smooth-muscle tumors with unusual growth patterns: imaging with pathologic correlation.

Cohen DT, Oliva E, Hahn PF, Fuller AF Jr, Lee SI.

AJR Am J Roentgenol. 2007 Jan;188(1):246-55. Review.

PMID:
17179374
10.

Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.

Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A; Gynecologic Cancer Program of Dana Farber-Harvard Cancer Center.

Gynecol Oncol. 2006 Oct;103(1):160-4. Epub 2006 Mar 29.

PMID:
16566993
11.

Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.

Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.

J Pain Symptom Manage. 2005 Dec;30(6):563-9.

12.

A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.

Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF Jr, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA; Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare.

Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1035-41.

13.
14.

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.

Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP.

Br J Cancer. 2005 Jul 11;93(1):54-9.

15.

Quality of life in advanced ovarian cancer: identifying specific concerns.

Houck K, Avis NE, Gallant JM, Fuller AF Jr, Goodman A.

J Palliat Med. 1999 Winter;2(4):397-402.

PMID:
15859780
16.

Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.

Penson RT, Seiden MV, Goodman A, Fuller AF Jr, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM; Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare.

Gynecol Oncol. 2004 Jun;93(3):702-7.

PMID:
15196868
17.

Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.

Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, Seiden MV.

Gynecol Oncol. 2004 Apr;93(1):98-106.

PMID:
15047220
18.

Intraoperative radiation therapy in the management of gynecologic and genitourinary malignancies.

del Carmen MG, Eisner B, Willet CG, Fuller AF.

Surg Oncol Clin N Am. 2003 Oct;12(4):1031-42. Review.

PMID:
14989131
19.

The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.

Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A.

Gynecol Oncol. 2004 Feb;92(2):648-52.

PMID:
14766261
20.

Phase II trial of anastrozole in women with asymptomatic müllerian cancer.

del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV.

Gynecol Oncol. 2003 Dec;91(3):596-602.

PMID:
14675683
21.

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.

Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF Jr, Wilson KS, Puchalski TA, Supko JG, Seiden MV.

Gynecol Oncol. 2003 Sep;90(3):610-8.

PMID:
13678734
22.

Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary.

Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF.

Gynecol Oncol. 2002 Jun;85(3):459-63.

PMID:
12051874
24.

Endometrial cancer in women 40 years old or younger.

Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF.

Gynecol Oncol. 2001 Nov;83(2):388-93.

PMID:
11606102
25.

A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.

Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA.

Cancer. 2001 Sep 1;92(5):1156-67.

PMID:
11571729
26.

Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva.

Penson RT, Fuller AF Jr.

J Clin Oncol. 2001 May 15;19(10):2767-8. No abstract available.

PMID:
11352972
27.

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.

Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV.

Gynecol Oncol. 2001 May;81(2):206-12.

PMID:
11330951
28.

Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva.

Penson RT, Fuller AF Jr.

J Clin Oncol. 2001 Apr 15;19(8):2364-5. No abstract available.

PMID:
11304789
29.

Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel.

Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV.

Int J Gynecol Cancer. 2000 Jan;10(1):33-41.

PMID:
11240649
30.

Intraoperative radiation therapy in the treatment of pelvic gynecologic malignancies: a review of fifteen cases.

del Carmen MG, McIntyre JF, Fuller AF, Nikrui N, Goodman A.

Gynecol Oncol. 2000 Dec;79(3):457-62.

PMID:
11104619
31.

Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis.

Houck K, Nikrui N, Duska L, Chang Y, Fuller AF, Bell D, Goodman A.

Obstet Gynecol. 2000 Jun;95(6 Pt 1):839-43.

PMID:
10831977
32.

Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.

Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.

Clin Cancer Res. 1999 Nov;5(11):3488-99.

33.

A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.

Duska LR, Penson R, Supko JG, Finkelstein DM, Makastorsis T, Gallagher J, Borden K, Goodman A, Fuller AF, Nikrui N, Seiden MV.

Clin Cancer Res. 1999 Jun;5(6):1299-305.

34.

Epithelial ovarian carcinoma in the reproductive age group.

Duska LR, Chang YC, Flynn CE, Chen AH, Goodman A, Fuller AF, Nikrui N.

Cancer. 1999 Jun 15;85(12):2623-9.

PMID:
10375111
35.

Predictors of recurrence in surgical stage II endometrial adenocarcinoma.

Feltmate CM, Duska LR, Chang Y, Flynn CE, Nikrui N, Kiggundu E, Goodman A, Fuller AF, McIntyre JF.

Gynecol Oncol. 1999 Jun;73(3):407-11.

PMID:
10366468
36.

Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.

Lane AH, Lee MM, Fuller AF Jr, Kehas DJ, Donahoe PK, MacLaughlin DT.

Gynecol Oncol. 1999 Apr;73(1):51-5.

PMID:
10094880
37.

Recurrent psammocarcinoma of the peritoneum with complete response to tamoxifen therapy.

Molpus KL, Wu H, Fuller AF Jr.

Gynecol Oncol. 1998 Feb;68(2):206-9.

PMID:
9514798
38.

Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy.

Schorge JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AF Jr.

Gynecol Oncol. 1997 Jul;66(1):31-5.

PMID:
9234917
39.

Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice.

Molpus KL, Koelliker D, Atkins L, Kato DT, Buczek-Thomas J, Fuller AF Jr, Hasan T.

Int J Cancer. 1996 Nov 27;68(5):588-95.

40.

The effect of postsurgical therapy on stage III endometrial carcinoma.

Schorge JO, Molpus KL, Goodman A, Nikrui N, Fuller AF Jr.

Gynecol Oncol. 1996 Oct;63(1):34-9.

PMID:
8898165
41.

Patterns of pulmonary metastasis from uterine cancer.

Bouros D, Papadakis K, Siafakas N, Fuller AF Jr.

Oncology. 1996 Sep-Oct;53(5):360-3.

PMID:
8784468
42.

Natural history of patients with pulmonary metastases from uterine cancer.

Bouros D, Papadakis K, Siafakas N, Fuller AF Jr.

Cancer. 1996 Aug 1;78(3):441-7.

PMID:
8697389
43.

Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature.

Goodman A, Zukerberg LR, Rice LW, Fuller AF, Young RH, Scully RE.

Gynecol Oncol. 1996 Apr;61(1):54-60. Review.

PMID:
8626118
44.

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.

Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller AF Jr.

Gynecol Oncol. 1996 Mar;60(3):412-7.

PMID:
8774649
45.

Histologic transformation of benign endometriosis to early epithelial ovarian cancer.

Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA.

Gynecol Oncol. 1996 Feb;60(2):238-44.

PMID:
8631545
46.

Postoperative management of patients with stage Ib endometrial carcinoma.

Sainz de la Cuesta R, Goff BA, Nikrui N, Flynn DF, Fuller AF Jr.

Eur J Gynaecol Oncol. 1996;17(5):338-41.

PMID:
8933825
47.

Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases.

Kato DT, Ferry JA, Goodman A, Sullinger J, Scully RE, Goff BA, Fuller AF Jr, Rice LW.

Gynecol Oncol. 1995 Dec;59(3):384-9.

PMID:
8522260
48.

Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy.

Muntz HG, Jones MA, Goff BA, Fuller AF Jr, Nikrui N, Rice LW, Tarraza HM.

Cancer. 1995 Oct 1;76(7):1209-13.

PMID:
8630899
49.

Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms.

Sainz de la Cuesta R, Goff BA, Fuller AF Jr, Nikrui N, Eichhorn JH, Rice LW.

Obstet Gynecol. 1994 Jul;84(1):1-7.

PMID:
8008300
50.

Prognostic significance of DNA content in epithelial ovarian cancer.

Gajewski WH, Fuller AF Jr, Pastel-Ley C, Flotte TJ, Bell DA.

Gynecol Oncol. 1994 Apr;53(1):5-12.

PMID:
8175021

Supplemental Content

Loading ...
Support Center